Flavia Borellini
Fortuna: 5 M $ al 30/09/2026
Fortuna: 5 M $ al 30/09/2026
Flavia Borellini currently works at Cantargia AB, as Independent Director from 2020, Revolution Medicines, Inc., as Independent Director from 2021, Kartos Therapeutics, Inc., as Director from 2018, and Pliant Therapeutics, Inc., as Independent Director from 2026.
Dr. Borellini also formerly worked at Acerta Pharma BV, as Chief Executive Officer from 2016 to 2019, Viracta Therapeutics, Inc., as Independent Director from 2021 to 2025, AstraZeneca PLC, as VP-Global Product & Portfolio Strategy from 2018 to 2020, Onyx Pharmaceuticals, Inc., as Vice President-Program Leadership from 2012 to 2013, and Roche Group, as Member.
Dr. Borellini received her doctorate degree from Università degli Studi di Modena e Reggio Emilia.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 18/06/2026 | 26.215 ( 0,01 % ) | 5 M $ | 30/09/2026 | |
| 09/07/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Director/Miembro de la Junta | 22/06/2021 |
| CANTARGIA AB | Director/Miembro de la Junta | 01/10/2020 |
| PLIANT THERAPEUTICS, INC. | Director/Miembro de la Junta | 09/07/2026 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Director/Miembro de la Junta | 01/02/2018 |
| Empresas | Cargo | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Director/Miembro de la Junta | 05/02/2025 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2020 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Director Ejecutivo | 01/02/2019 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/10/2013 |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company focuses on discovering and developing novel therapies for the treatment of fibrosis | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Health Technology |
Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.